Getting skinny on fat jabs left me with a HOLE in my throat and that wasn't the worst of it – I beg you, DON'T do it!
WHEN Aimee Chapman began using fat jabs just over a year ago, she never expected to end up in hospital fighting for her life, with a hole in her throat.
The 34-year-old lost four stone in a matter of months, but was left suffering complications so severe that doctors were left baffled as to how to help her. Now she says she regrets ever taking the injections.
12
12
12
Aimee was rushed to hospital just a few months after starting on the jabs, where doctors discovered a hole in her oesophagus due to frequent vomiting, and a failing liver.
Aimee told The Sun: "They were trying all sorts of things to get my liver levels back to normal. It was failing.
"They had said it was down to the weight-loss jab, but they didn't know why or how to fix it.
"There was so little out there medical-wise, doctors didn't know how to fix it.
"I was terrified. It all happened so quickly and I hadn't realised how serious it was until I was transferred and it sunk in that it was worse than I thought it was.'
And months after her ordeal, Aimee's waist-length hair began falling out in clumps.
She's now warning others against using the popular jabs.
The 34-year-old began using the GLP-1-class weight loss injections in March last year.
She claims it was for her health, as she'd been diagnosed with fibromyalgia 15 years ago.
The condition causes widespread pain, fatigue, headaches and mood problems, and is incurable.
But GPs advise exercise, therapy and antidepressants for managing symptoms.
Weight Loss Jabs - Pros vs Cons
Aimee, who lives in Southampton, Hampshire, said: "I'd never even thought about it until I saw a post on social media saying you can just buy [weight-loss jabs].
"I noticed that as my weight changed, I was taken less seriously by doctors. My thinking was that if I could weigh less, I would at least get taken a bit more seriously.
"It wasn't about getting thinner or looking better for me. That hadn't even crossed my mind."
The family of drugs known as GLP-1 RAs were originally developed to treat diabetes - one notable example is Ozempic.
12
12
Now, the same technology has been deployed for weight loss, in the form of drugs like Mounjaro and Wegovy.
They suppress a patient's appetite, mimicking hormones naturally released by the gut to signal fullness.
'In denial'
Aimee bought her jabs from an online pharmacy. She paid around £200 for a month's worth of them.
She lost a whopping four stone when she first began using the injectables, dropping from 14 stone to just 10 stone in four months.
However, in June last year, Aimee - who is married to Christopher Chapman, 41, a security officer - began feeling unwell and was barely able to eat.
She says: '[After a few months of using the jabs] I started noticing I didn't have a lot of energy, I couldn't really do much. I was only eating a couple of times a week.
"I stopped being able to walk. I would take a couple of steps and have to stop.'
I was throwing up all the time and started throwing up blood. I was sick between 50 and 60 times
Aimee
But worryingly, Aimee couldn't stop being sick.
Feeling and being sick are among the most common side effects when taking GLP-1s, thought to affect around one in 10 people on them.
"I was throwing up all the time and started throwing up blood,' says Aimee. 'I was sick between 50 and 60 times.
"I collapsed a couple of times. My husband came home and found me passed out in the hallway one night.
"I was in a bit of denial about it being linked to the jab because I was fine up until now. I just thought I was poorly and it was some sort of virus."
'Could have died'
When Aimee began experiencing chest pains a month later, she went to Winchester Hospital's A&E.
It was then that doctors discovered she had developed a hole in her oesophagus that was leaking air around her heart and lungs.
Aimee was admitted to the intensive care unit on July 12, and her blood pressure and potassium levels began to plummet.
Then, she was rushed to ICU at Southampton General Hospital when doctors noticed her liver function was deteriorating.
An organ transplant was considered when Aimee's liver began showing signs of failure.
But luckily, Aimee was able to return home after 11 days in hospital.
What are the other side effects of weight loss jabs?
Like any medication, weight loss jabs can have side effects.
Common side effects of injections such as Ozempic include:
Nausea: This is the most commonly reported side effect, especially when first starting the medication. It often decreases over time as your body adjusts.
Vomiting: Can occur, often in conjunction with nausea.
Diarrhea: Some people experience gastrointestinal upset.
Constipation: Some individuals may also experience constipation.
Stomach pain or discomfort: Some people may experience abdominal pain or discomfort.
Reduced appetite: This is often a desired effect for people using Ozempic for weight loss.
Indigestion: Can cause a feeling of bloating or discomfort after eating.
Serious side effects can also include:
Pancreatitis: In rare cases, Ozempic may increase the risk of inflammation of the pancreas, known as pancreatitis, which can cause severe stomach pain, nausea, and vomiting.
Kidney problems: There have been reports of kidney issues, including kidney failure, though this is uncommon.
Thyroid tumors: There's a potential increased risk of thyroid cancer, although this risk is based on animal studies. It is not confirmed in humans, but people with a history of thyroid cancer should avoid Ozempic.
Vision problems: Rapid changes in blood sugar levels may affect vision, and some people have reported blurry vision when taking Ozempic.
Hypoglycemia (low blood sugar): Especially if used with other medications like sulfonylureas or insulin.
Her liver made a full recovery and the hole in her throat healed itself.
But the 34-year-old was told she would never be able to touch GLP-1 jabs again.
"After coming out of ICU, the nurse told me this has happened because of these jabs and I can never take one ever again even if I had type 2 diabetes,' Aimee says.
"I don't think they know whether this was a general side-effect or whether this was a rare case. I was really surprised about how much of my body it affected.
"I was told the hole in the oesophagus can kill people and I may have needed a new liver. They said I could've died."
Liver issues are not a common side effect of weight loss injections, but there have been a isolated reports of people developing liver injury after taking the jabs.
On the other hand, research has indicated that GLP-1s could lower the risk of liver disease, as people with obesity have a higher risk of developing a particular type called fatty liver disease.
Some weight loss jab users develop gallstones or an inflamed gallbladder, which can be connected to liver function.
12
'Don't do it'
In September 2024, a few months after her ordeal Aimee began to notice her hair was coming out in clumps.
She believes this is related to a vitamin B12 deficiency linked to being on the weight loss jabs.
Aimee said: "[The hair loss] kept happening and the handfuls kept getting bigger. I would be so sad. My hair was just above my bum when I went into hospital.
'My husband just said why don't you just cut it off? My hair was such a massive part of my identity and to cut it off just felt really traumatic. But I said to myself it was just hair, it'll grow back.
"This feels like another result of the injections.'
The 34-year-old was diagnosed as vitamin B deficient after blood tests in October.
She now has to get quarterly vitamin B12 injections.
Aimee, who doesn't work due to her disability, is now calling on others who are considering using the injectables to do their research and consult a doctor.
'I'm not going to tell people what they can and can't take but I do believe more research needs to be done into these jabs,' she says.
"I regret ever taking them. I'd say to other people thinking about trying them, don't do it online, go through your doctor who can give you blood tests and check how you're doing."
Everything you need to know about fat jabs
Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases.
Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK.
Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market.
Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year.
How do they work?
The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight.
They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists.
They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high.
Can I get them?
NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.
Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure.
GPs generally do not prescribe the drugs for weight loss.
Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk.
Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health.
Are there any risks?
Yes – side effects are common but most are relatively mild.
Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea.
Dr Sarah Jarvis, GP and clinical consultant at patient.info, said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.'
Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia.
Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health.
Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
June 20 (Reuters) - Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly (LLY.N), opens new tab and Novo Nordisk ( opens new tab could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday. About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite. The initial Wall Street estimates for muscle-preserving therapies follow promising mid-stage results from experimental drugs developed by Regeneron (REGN.O), opens new tab and Scholar Rock (SRRK.O), opens new tab. Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week. Analysts have projected that obesity drugs sales could reach $150 billion a year by the early 2030s. The unmet need to preserve muscle will grow with the use of GLP-1 drugs for obesity, said TD Cowen analyst Tyler Van Buren. Doctors have raised concerns that patients may experience a decrease in overall strength due to muscle loss associated with Zepbound and Wegovy, while experts suggest that more muscle can help patients maintain long-term weight loss. Van Buren said that the first such treatment could launch by 2028, although regulatory challenges remain because these treatments must demonstrate additional health benefits to secure approval. "We believe quality of weight loss and lean mass preservation ... is far too important for long-term health outcomes to be ignored and that this will be figured out," Van Buren said. Some of the new drugs target the myostatin protein, which is associated with muscle growth, and are expected to see broader use due to their superior safety profile, capturing the majority of the market share, Van Buren said. Other drugs target activin, a protein with multiple biological functions. Van Buren said that activin-based drugs will be reserved for patients at higher risk of losing strength, forecasting sales of about $5 billion by 2035.
Telegraph
an hour ago
- Telegraph
Sir Ian McGeechan: Cancer treatment has worked
Sir Ian McGeechan has given a positive update on his cancer diagnosis, saying 'the treatment has worked'. The British and Irish Lions legend revealed he had been diagnosed with prostate cancer in an interview with Telegraph Sport last month. The Scot, who was Lions head coach for four tours, said then that he had undergone six weeks of radiotherapy treatment, and would have to wait another six weeks to discover whether it had been successful. Speaking to fellow Telegraph columnist Will Greenwood during Sky Sports' coverage of the opening Lions game against Argentina, McGeechan revealed he had since received good news about the condition. Asked about his health, McGeechan answered: 'All good, thank you, the treatment has worked. Fine.' Host Alex Payne added: 'So glad to hear that Geech has had the all clear'. McGeechan is perhaps the ultimate Lions legend after his unparalleled career both as a player and coach. The 78-year-old was inundated with messages after his Telegraph interview, with the game of rugby uniting to wish him well. McGeechan has been coaching at Doncaster Knights as he maintains his illustrious career in the game, some 51 years after he first went on a Lions tour as a player in 1974, before being selected again in 1977. McGeechan was then head coach in 1989, 1993, 1997 and 2009, as well as coach of the midweek side in 2005. When revealing his cancer diagnosis, McGeechan said he hoped his honesty would inspire others to get tested. 'I don't want to make a big thing of it, but it is important to get the message out about urging people to get tested,' he said. 'I said that to our players here. I said to them that they make sure they get themselves tested. If you are younger, it is more important. 'Hopefully this interview can be educational. What I would say to people is don't back off it. It is a blood test, it is not what you always think. Just get it done. I have good people looking after me. It is the very good side of the NHS. The staff of the Bexley Cancer Wing at St James's Hospital in Leeds have been brilliant. 'When I had my last treatment, from the receptionist to the radiographer, they all said: 'Well done, good luck, have a happy time.' Everyone. They all knew. When they are looking up your details and you are going on to your next step, it says which number of treatment is it, and it is what they say to every person when they get to their last treatment, which I think is great. That support and the environment is so positive. What will be, will be.'
Telegraph
2 hours ago
- Telegraph
NHS could face cuts under assisted dying law, warns Streeting
NHS services could face cuts to cover the cost of carrying out assisted deaths, the Health Secretary has warned. Under the Bill passed on Friday, the NHS will be expected to carry out the assisted dying procedures. Analysis suggests that implementation of assisted dying may cost the health service close to half a billion pounds within a decade, with each death costing the taxpayer more than £15,000. Assisted dying is set to be legalised in England and Wales after a historic vote saw it voted through by a majority of 23 MPs. However, Wes Streeting – who voted against the Bill – is understood to be deeply concerned about the impact it might have on an overstretched NHS. Speaking ahead of the vote, he warned: 'There isn't money allocated to set up the service in the Bill', while stressing that the Government would respect the decision of the House. Previously, he had warned there would be 'choices and trade-offs' to make, saying 'any new service comes at the expense of other competing pressures and priorities'. Last week, the Health Secretary said the NHS was 'in a fight for its life' as he described his mission to turn the service around. A number of MPs who opposed the Bill have raised concerns that assisted dying could take resources away from patients. On Tuesday, Dame Siobhain McDonagh, a Labour MP who voted against the legislation, said it could become 'the Trojan horse that breaks the NHS', saying it would 'rob our stretched NHS of much-needed resources'. The impact assessment of the Terminally Ill Adults (End of Life) Bill estimates that up to 28,317 people will die by state assisted suicide within the first 10 years of rollout. This rises from 647 in year one to more than 4,500 by 2038, and could mean costs of £429 million for the NHS over the decade. The spending includes educating all health and social care staff, training the doctors and nurses involved in the assisted dying service, setting up a regulator, as well as the costs of the lethal drugs themselves. Training staff is set to be the biggest cost – especially as the service is created. This could cost up to £35.5 million in the first year if all involved got the highest level of training available with no one opting out. There would then be recurring annual costs of between £10-22 million. Staff costs could reach £72 million over 10 years, with up to seven staff working for 32 hours per assisted death, it concludes. None of the calculations include the lost productivity and knock-on effects of the work the doctors are no longer able to carry out as a result. The impact assessment puts the cost of the drugs required at around £15 per person. However, independent experts have said it is highly likely to cost more. The Government also predicts a regulator and panel to assess cases would cost up to £13.6 million every year to run. The assessment suggests that overall, the Government could save money as a result of the earlier deaths, with overall savings of more than £640 million. Some of these savings could be made by the NHS. By 2038, health services could save up to £71.5 million a year on end-of-life care, because of the savings from not providing costly hospital care for cancer. Assisted dying is now on course to be available by 2029. Adults with a terminal illness and less than six months to live will be eligible under the new law. The law passed despite widespread opposition, with opponents raising concerns over the dropping of a requirement for a High Court judge to sign off on all assisted dying cases. Critics also warned that the law would 'normalise the choice of death over life, care, respect and love'.
